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Abstract
We present the case of a patient with a heart failure episode induced by acute right ventricular 
pacing. After reversal of beta-blockers because of chronic obstructive pulmonary disease 
(COPD) exacerbation, the following sinus tachycardia caused a 2:1 atrioventricular block and 
consequent continuous right ventricular pacing. He was treated with the selective If inhibitor 
ivabradine, that reduced both ventricular pacing percentage and heart rate without affecting 
atrioventricular conduction. Ivabradine may be a valuable option in treatment of patients with 
atrioventricular conduction disturbances.                                                       
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Introduction
Congestive heart failure is a common health problem. The burden of this condition is likely to 
increase as a result of an aging population and improved survival rates after acute myocardial 
infarction. In patients with symptomatic chronic heart failure, beta-blockers reduce mortality 
and hospital admission for worsening heat failure (Class I, level of evidence A) [1]. However, 
many heart failure patients still do not receive a beta-blocker or receive a suboptimal dose, 
because  side  effects  may   limit   their  use.  Both COPD   and  atrio-ventricular   conduction 
disturbances  may forbid dosage up-titration.                                                            
Case   Report                                                                                              
In January 2010, a 79-year-old man with a ten year history of post-ischaemic dilated 
cardiomyopathy was admitted with dyspnoea at rest, i.e. NYHA functional class IV, after he 
reduced bisoprolol dose because of COPD exacerbation. He had received a dual chamber ICD 
(Epic DR V- 239, St. Jude Medical Inc, USA) in July 2009 because of an episode of sustained 
ventricular tachycardia. Coronary artery disease progression had been ruled out by angiography 
six months before. Apart from beta-blocker, he received a standard heart failure medication 
(including ACE inhibitor, digitoxin, furosemide and spironolactone). On physical examination, 
a grade 2 holosystolic murmur at the left axillary's border at pulmonary auscultation basal rales 
were detected, blood pressure was 120/80 mmHg, and pulse was regular (105 bpm). Physical 
examination was otherwise unremarkable. The ECG showed sinus rhythm, with right ventricular 
pacing and a heart rate at 105 bpm (Figure 1A).
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Figure 1A. ECG at admission: sinus tachycardia with right ventricular pacing
Figure 1B. ICD interrogation at admission reveals a 2:1 atrio-ventricular block
Chest X-ray demonstrated cardiomegaly with signs of pulmonary congestion. Laboratory test 
results revealed elevated but stable values of BUN (96 mg/dl) and creatinine (2.01 mg/dl). NT-
pro-BNP was 970.9 pg/ml. All other laboratory parameters including thyroid function were 
normal. Echocardiography demonstrated left ventricular (LV) dilation with an ejection fraction 
of 39 % calculated by the Teichholz' method. Color Doppler imaging demonstrated mitral 
regurgitation grade 3. At ICD interrogation 2:1 AV block with a narrow QRS was recognized 
(Figure 1B). We hypothesized a frequency dependent AV block. Thus, to slow heart rate the 
patient started the selective If channel inhibitor ivabradine at the dose of 5 mg bid, bisoprolol 
was stopped. The patient reported a prompt and marked symptomatic improvement. ECG 
showed sinus rhythm, with 1st degree AV block and left anterior hemiblock, without RVP 
(Figure 2). At noninvasive pacing stimulation (NIPS) a 2:1 AV conduction block was recorded 
with a drive of 600 ms. Three days after admission the patient was asymptomatic at rest and was 
discharged with a resting heart rate of 51 bpm. Echocardiography showed a slight increase of 
the left ventricular ejection fraction to 45%, and a reduction of mitral regurgitation to grade 2. 
Therefore, due to unexpected functional improvement, adequate heart rate control and reduction 
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of right ventricular pacing he was discharged. He is now in stable NYHA class II. No adverse 
effects to ivabradine treatment have been reported by the patient.
Figure 2. ECG at discharge: sinus bradycardia without right ventricular pacing
Conclusion
Faster resting heart rates represent per se a risk factor for cardiovascular mortality and HF 
hospitalization, despite optimal HF therapy. Heart rate may condition left ventricular filling, 
myocardial oxygen demand and coronary perfusion time. [2-3] Beta-blockers remain the 
therapy of choice in all patients with systolic heart failure, but they may worsen AV conduction 
and increase RV pacing percentage. Nevertheless, reduction of cumulative RV pacing as far as 
possible should be achieved in ICD patients. Several studies have demonstrated detrimental 
effects of right ventricular (RV) apical pacing on cardiac function [4-5]. The direct electric 
stimulation   of   the   RV   apex   causes   an   abnormal   activation   sequence   and   mechanical 
dyssynchrony. In patients with LV dysfunction, these effects are more pronounced and 
permanent RV apical pacing may cause a higher risk of morbidity and mortality at long-term 
follow-up.
Sharma et al. showed in a post hoc analysis of the DAVID trial that DDDR RV pacing >40% 
was a univariate predictor of death and hospitalization for heart failure [4]. Smit et al. studied 
the effect of RV pacing on heart failure events in asymptomatic (NYHA class I) patients. 
Cumulative RV pacing >50% was associated with an increase in heart failure events and was an 
independent predictor of ICD shocks [5].                                                                 
Ivabradine is a specific inhibitor of the If current of the sinus node, that induces a selective and 
dose dependent HR reduction pure HR lowering agent without effects on atrioventricular 
conduction or contractility. The SHIFT study has recently assessed that heart rate reduction by 
direct sinus node inhibition can reduce cardiovascular mortality or HF hospitalization by 18% in 
patients with chronic heart failure and left-ventricular systolic dysfunction. In particular, this 
beneficial effect was mainly driven by a favourable effect on HF death/hospital admission (RRR 
26%) [6] This case demonstrates that RV pacing may be reduced by controlling heart rate at rest 
by using ivabradine. Pure heart rate reduction without effect on AV conduction obtained by 
ivabradine may be a valuable option in order to avoid increase in RV pacing percentage in dual 
chamber ICD and pacemaker recipients when sophisticated algorhithms are not available or 
drug induced atrio-ventricular block may be detrimental. Further studies are needed to evaluate 
the use of Ivabradine to control HR in dual chamber pacemaker and ICD recipients with 
moderate to severe left ventricular dysfunction and atrio-ventricular conduction disturbances in 
order to obtain HR control without promoting right ventricular pacing.                      
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